The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Schorno Dean L since 2011.
This trader's CIK number is 1509688.
At the time of last reporting, Schorno Dean L was the EVP & Chief Financial Officer of Rigel Pharmaceuticals Inc. (stock ticker symbol RIGL).
Also see all insider trading activities at Rigel Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2014 | GHDX | 0 | $0 | 8,000 | $210,848 | 8,000 | $144,280 |
| 2013 | GHDX | 0 | $0 | 28,625 | $960,379 | 28,625 | $473,502 |
| 2012 | GHDX | 0 | $0 | 13,755 | $411,816 | 9,000 | $84,510 |
| 2011 | GHDX | 0 | $0 | 6,276 | $150,871 | 1,276 | $3,674 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | RIGL | 0 | $0 | 3,770 | $80,614 | 0 | $0 |
| 2024 | RIGL | 0 | $0 | 12,628 | $14,339 | 0 | $0 |
| 2023 | RIGL | 0 | $0 | 5,389 | $8,945 | 0 | $0 |
| 2019 | RIGL | 50,000 | $106,500 | 0 | $0 | 0 | $0 |
2. Rigel Pharmaceuticals Inc (RIGL)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-06-10 | GHDX | Option Ex | 4,000 | 18.04 | 72,140 |
| 2014-06-10 | GHDX | Sale | 4,000 | 27.62 | 110,488 |
| 2014-05-09 | GHDX | Option Ex | 4,000 | 18.04 | 72,140 |
| 2014-05-09 | GHDX | Sale | 4,000 | 25.09 | 100,360 |
| 2013-12-09 | GHDX | Option Ex | 3,000 | 17.25 | 51,765 |
| 2013-12-09 | GHDX | Sale | 3,000 | 33.25 | 99,762 |
| 2013-11-08 | GHDX | Sale | 3,000 | 33.36 | 100,089 |
| 2013-11-08 | GHDX | Option Ex | 3,000 | 17.33 | 51,989 |
| 2013-09-06 | GHDX | Option Ex | 4,000 | 17.25 | 69,020 |
| 2013-09-06 | GHDX | Sale | 4,000 | 32.90 | 131,600 |
| 2013-08-09 | GHDX | Option Ex | 4,000 | 17.18 | 68,720 |
| 2013-08-09 | GHDX | Sale | 4,000 | 33.15 | 132,580 |
| 2013-07-09 | GHDX | Sale | 4,000 | 33.81 | 135,236 |
| 2013-07-09 | GHDX | Option Ex | 4,000 | 17.33 | 69,320 |
| 2013-06-10 | GHDX | Sale | 4,000 | 35.88 | 143,524 |
| 2013-06-10 | GHDX | Option Ex | 4,000 | 17.33 | 69,320 |
| 2013-05-09 | GHDX | Option Ex | 4,000 | 17.18 | 68,720 |
| 2013-05-09 | GHDX | Sale | 4,000 | 36.02 | 144,088 |
| 2013-01-09 | GHDX | Option Ex | 2,625 | 9.39 | 24,648 |
| 2013-01-09 | GHDX | Sale | 2,625 | 28.00 | 73,500 |
| 2012-12-11 | GHDX | Sale | 3,000 | 28.00 | 84,000 |
| 2012-12-11 | GHDX | Option Ex | 3,000 | 9.39 | 28,170 |
| 2012-11-09 | GHDX | Option Ex | 200 | 9.39 | 1,878 |
| 2012-11-09 | GHDX | Sale | 200 | 28.00 | 5,600 |
| 2012-11-12 | GHDX | Option Ex | 2,800 | 9.39 | 26,292 |
| 2012-11-12 | GHDX | Sale | 2,800 | 28.00 | 78,400 |
| 2012-10-12 | GHDX | Option Ex | 3,000 | 9.39 | 28,170 |
| 2012-10-12 | GHDX | Sale | 3,000 | 33.79 | 101,358 |
| 2012-05-15 | GHDX | Sale | 1,000 | 33.69 | 33,686 |
| 2012-04-16 | GHDX | Sale | 1,000 | 27.98 | 27,980 |
| 2012-03-15 | GHDX | Sale | 1,000 | 31.08 | 31,080 |
| 2012-02-15 | GHDX | Sale | 755 | 28.76 | 21,713 |
| 2012-01-17 | GHDX | Sale | 1,000 | 28.00 | 27,999 |
| 2011-06-15 | GHDX | Sale | 1,000 | 25.91 | 25,909 |
| 2011-05-12 | GHDX | Sale | 1,000 | 26.48 | 26,479 |
| 2011-04-14 | GHDX | Sale | 1,000 | 25.32 | 25,319 |
| 2011-03-15 | GHDX | Sale | 1,000 | 23.79 | 23,787 |
| 2011-02-15 | GHDX | Sale | 1,000 | 22.51 | 22,506 |
| 2011-01-13 | GHDX | Option Ex | 1,276 | 2.88 | 3,674 |
| 2011-01-13 | GHDX | Sale | 1,276 | 21.06 | 26,871 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-04 | RIGL | Sale | 2,036 | 20.92 | 42,595 |
| 2025-02-05 | RIGL | Sale | 1,734 | 21.93 | 38,019 |
| 2024-02-02 | RIGL | Sale | 5,601 | 1.13 | 6,329 |
| 2024-02-05 | RIGL | Sale | 7,027 | 1.14 | 8,010 |
| 2023-02-02 | RIGL | Sale | 5,389 | 1.66 | 8,945 |
| 2019-05-22 | RIGL | Buy | 50,000 | 2.13 | 106,500 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Schorno Dean L (EVP & Chief Financial Officer of Rigel Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.